LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

Search

Akebia Therapeutics Inc

Gesloten

SectorGezondheidszorg

3.54 -2.75

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

3.51

Max

3.69

Belangrijke statistieken

By Trading Economics

Inkomsten

29M

6.1M

Verkoop

11M

57M

EPS

0.025

Winstmarge

10.66

Werknemers

181

EBITDA

20M

14M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+84.93% upside

Dividenden

By Dow Jones

Volgende Winsten

7 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

395M

1B

Vorige openingsprijs

6.29

Vorige sluitingsprijs

3.54

Nieuwssentiment

By Acuity

28%

72%

82 / 380 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bullish Evidence

Akebia Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

13 jun 2025, 22:33 UTC

Acquisities, Fusies, Overnames

Millicom to Acquire Telefonica Ecuador for $380 Million

13 jun 2025, 23:50 UTC

Acquisities, Fusies, Overnames

Trump and Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- 2nd Update

13 jun 2025, 23:20 UTC

Acquisities, Fusies, Overnames

Trump and Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- Update

13 jun 2025, 23:09 UTC

Acquisities, Fusies, Overnames

Trump, Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- WSJ

13 jun 2025, 23:03 UTC

Acquisities, Fusies, Overnames

Trump, Nippon Steel Reach National-Security Agreement on U.S. Steel Deal --WSJ

13 jun 2025, 22:18 UTC

Acquisities, Fusies, Overnames

Millicom to Acquire Telefonica Ecuador for $380M

13 jun 2025, 22:04 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Better Data Facilitate Investments In Oil Patch -- Market Talk

13 jun 2025, 21:42 UTC

Acquisities, Fusies, Overnames

Anne Wojcicki Wins Bidding for 23andMe -- 2nd Update

13 jun 2025, 21:35 UTC

Acquisities, Fusies, Overnames

Bunge: Outside Date Extended to July 3

13 jun 2025, 21:35 UTC

Acquisities, Fusies, Overnames

Bunge: Subject to Satisfaction of Remaining Conditions, Bunge and Sellers Expect to Complete Transaction July 2

13 jun 2025, 21:34 UTC

Acquisities, Fusies, Overnames

Bunge Gets Mexico Approval for Viterra Deal

13 jun 2025, 21:32 UTC

Acquisities, Fusies, Overnames

Bunge Gets China Approval for Viterra Deal

13 jun 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

13 jun 2025, 20:45 UTC

Acquisities, Fusies, Overnames

23andMe: TTAM Makes Binding Commitments for Additional Consumer Protections and Privacy Safeguards

13 jun 2025, 20:34 UTC

Acquisities, Fusies, Overnames

Anne Wojcicki Wins Bidding for 23andMe -- Update

13 jun 2025, 20:14 UTC

Acquisities, Fusies, Overnames

Nonprofit Controlled By 23andMe Co-Founder Anne Wojcicki Would Buy the DNA-Testing Company for $305 Million -- WSJ

13 jun 2025, 20:14 UTC

Acquisities, Fusies, Overnames

Anne Wojcicki Wins Bidding for 23andMe -- WSJ

13 jun 2025, 20:14 UTC

Acquisities, Fusies, Overnames

Regeneron Walks Away From 23andMe Acquisition After Wojcicki's Higher Bid -- WSJ

13 jun 2025, 19:30 UTC

Marktinformatie

U.S. Natural Gas Futures Post Moderate Gains -- Market Talk

13 jun 2025, 19:12 UTC

Marktinformatie

Oil Futures Jump As Israel Strikes Iranian Targets -- Market Talk

13 jun 2025, 19:04 UTC

Marktinformatie

Canada Military Spending Hike to Lift Long-Term Yields -- Market Talk

13 jun 2025, 18:54 UTC

Marktinformatie

Correction to Gold Settles Market Talk

13 jun 2025, 18:01 UTC

Marktinformatie

Gold Settles at Record High -- Market Talk

13 jun 2025, 17:40 UTC

Marktinformatie

U.S. Oil Rig Count Falls By 3 to 439 -- Market Talk

13 jun 2025, 17:21 UTC

Marktinformatie

Dollar Index, Commodities Rise -- Market Talk

13 jun 2025, 17:02 UTC

Acquisities, Fusies, Overnames

Advent Proposal Values Spectris at GBP37.63 Per Share, Company Said Monday -- WSJ

13 jun 2025, 17:02 UTC

Acquisities, Fusies, Overnames

KKR Is Preparing a Bid for High-Tech Instrument Maker Spectris, Sources Say -- WSJ

13 jun 2025, 17:02 UTC

Acquisities, Fusies, Overnames

Private-Equity Firm Is Vying With Advent for the U.K. Company, Sources Say -- WSJ

13 jun 2025, 17:02 UTC

Acquisities, Fusies, Overnames

KKR Making Competing Bid for Equipment Maker Spectris -- WSJ

13 jun 2025, 16:20 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Akebia Therapeutics Inc Prognose

Koersdoel

By TipRanks

84.93% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 6.75 USD  84.93%

Hoogste 8 USD

Laagste 6 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Akebia Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

4 ratings

4

Buy

0

Hold

0

Sell

Technische score

By Trading Central

2.345 / N/ASteun & Weerstand

Korte Termijn

Strong Bullish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

Bullish Evidence

Sentiment

By Acuity

82 / 380 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Akebia Therapeutics Inc

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.